Monitoring the Decrease in Susceptibility to Ribosomal RNAs Targeting Antimicrobials and Its Molecular Basis in Clinical Mycoplasma bovis Isolates over Time.

Mycoplasma bovis is considered an emerging threat to bovine production in industrialized countries. Its control depends on good husbandry and efficient chemotherapy practices. In France, clinical isolates collected after 2009 showed a drastic loss of susceptibility to most antimicrobials when compared with isolates collected in 1978-1979. The aim of the present study was to analyze the molecular mechanisms underlying the shift toward resistance to macrolides and tetracyclines and to assess whether the clinical origin of the isolates or their molecular subtypes could have influenced their pattern of evolution. We demonstrated that all M. bovis isolates collected as early as 2000 should already be considered resistant to tylosin, tilmicosin, and oxytetracycline, whatever the associated clinical signs. The shift toward resistance happened earlier for oxytetracycline and more progressively for tylosin/tilmicosin. Isolates belonging to the major subtype ST2 (n = 40) showed a homogeneous genotype for resistance, with combined alterations of G748A and A2058G in the 23S rRNA alleles for tylosin/tilmicosin and of A965T and A967T in the 16S rRNA alleles for oxytetracycline. The genotypes of ST3 or ST1 isolates (n = 9 and 25, respectively) in the process of becoming resistant were more varied. In recent years, the convergence of both ST2 and ST3 isolates toward the same resistance genotype suggests that the corresponding mutations have been selected for providing an appropriate balance between fitness cost and resistance.

[1]  S. De Vliegher,et al.  Short communication: In vitro antimicrobial susceptibility of Mycoplasma bovis isolates identified in milk from dairy cattle in Belgium, Germany, and Italy. , 2016, Journal of dairy science.

[2]  A. Heuvelink,et al.  Antimicrobial susceptibility of Mycoplasma bovis isolates from veal calves and dairy cattle in the Netherlands. , 2016, Veterinary microbiology.

[3]  S. Pereyre,et al.  Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment , 2016, Front. Microbiol..

[4]  I. Lysnyansky,et al.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility , 2016, Front. Microbiol..

[5]  J. Xin,et al.  Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China , 2015, The Journal of veterinary medical science.

[6]  F. Tardy,et al.  Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal , 2015, Applied and Environmental Microbiology.

[7]  J. Frey,et al.  Virulence, persistence and dissemination of Mycoplasma bovis. , 2015, Veterinary microbiology.

[8]  F. Tardy,et al.  Loss of diversity within Mycoplasma bovis isolates collected in France from bovines with respiratory diseases over the last 35 years. , 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[9]  R. Nicholas,et al.  16S rRNA Gene Mutations Associated with Decreased Susceptibility to Tetracycline in Mycoplasma bovis , 2014, Antimicrobial Agents and Chemotherapy.

[10]  S. Borriello,et al.  Antibiotics used most commonly to treat animals in Europe , 2014, Veterinary Record.

[11]  J. Dewulf,et al.  Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. , 2014, The Journal of antimicrobial chemotherapy.

[12]  F. Poumarat,et al.  Overall Decrease in the Susceptibility of Mycoplasma bovis to Antimicrobials over the Past 30 Years in France , 2014, PloS one.

[13]  D. Yogev,et al.  Acquired resistance to the 16-membered macrolides tylosin and tilmicosin by Mycoplasma bovis. , 2014, Veterinary microbiology.

[14]  J. Coetzee,et al.  Antimicrobial Drug Use in Cattle , 2013 .

[15]  S. Giguère.  Macrolides, Azalides, and Ketolides , 2013 .

[16]  J. Perez-Casal,et al.  Vaccination of feedlot cattle with extracts and membrane fractions from two Mycoplasma bovis isolates results in strong humoral immune responses but does not protect against an experimental challenge. , 2013, Vaccine.

[17]  J. Poehlsgaard,et al.  Inhibition of Protein Synthesis on the Ribosome by Tildipirosin Compared with Other Veterinary Macrolides , 2012, Antimicrobial Agents and Chemotherapy.

[18]  M. Bodmer,et al.  Herd-specific strains of Mycoplasma bovis in outbreaks of mycoplasmal mastitis and pneumonia. , 2012, Veterinary microbiology.

[19]  J. Poehlsgaard,et al.  Visualizing the 16-membered ring macrolides tildipirosin and tilmicosin bound to their ribosomal site. , 2012, ACS chemical biology.

[20]  A. Aydin,et al.  Blinded, controlled field trial of two commercially available Mycoplasma bovis bacterin vaccines in veal calves. , 2011, Vaccine.

[21]  D. Wilson,et al.  Mycoplasma bovis infections in cattle. , 2011, Journal of veterinary internal medicine.

[22]  R. Nicholas.  Bovine mycoplasmosis: silent and deadly , 2011, Veterinary Record.

[23]  D. Calavas,et al.  Mycoplasmoses of ruminants in France: recent data from the national surveillance network , 2010, BMC veterinary research.

[24]  I. Lysnyansky,et al.  In vitro antimicrobial susceptibility of Mycoplasma bovis isolated in Israel from local and imported cattle. , 2009, Veterinary microbiology.

[25]  M. Ehrenberg,et al.  Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency , 2009, The EMBO journal.

[26]  S. Pereyre,et al.  Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. , 2008, The Journal of antimicrobial chemotherapy.

[27]  M. Marenda,et al.  Suppression subtractive hybridization as a basis to assess Mycoplasma agalactiae and Mycoplasma bovis genomic diversity and species-specific sequences. , 2005, Microbiology.

[28]  H. Ohya,et al.  Characterization and Molecular Analysis of Macrolide-Resistant Mycoplasma pneumoniae Clinical Isolates Obtained in Japan , 2004, Antimicrobial Agents and Chemotherapy.

[29]  J. Poehlsgaard,et al.  Ketolide Antimicrobial Activity Persists after Disruption of Interactions with Domain II of 23S rRNA , 2004, Antimicrobial Agents and Chemotherapy.

[30]  S. Pereyre,et al.  Mutations in 23S rRNA Account for Intrinsic Resistance to Macrolides in Mycoplasma hominis and Mycoplasma fermentans and for Acquired Resistance to Macrolides in M. hominis , 2002, Antimicrobial Agents and Chemotherapy.

[31]  F. Schluenzen,et al.  Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria , 2001, Nature.

[32]  V. Ramakrishnan,et al.  The Structural Basis for the Action of the Antibiotics Tetracycline, Pactamycin, and Hygromycin B on the 30S Ribosomal Subunit , 2000, Cell.

[33]  P. Hannan,et al.  Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. International Research Programme on Comparative Mycoplasmology. , 2000, Veterinary research.

[34]  B. Pettersson,et al.  Characterization of mycoplasmas by PCR and sequence analysis with universal 16S rDNA primers. , 1998, Methods in molecular biology.

[35]  S. Giguère,et al.  Antimicrobial therapy in veterinary medicine , 1994 .

[36]  J. Martel,et al.  Application of dot immunobinding on membrane filtration (MF dot) to the study of relationships within "M. mycoides cluster" and within "glucose and arginine-negative cluster" of ruminant mycoplasmas. , 1992, Veterinary microbiology.

[37]  F. Poumarat,et al.  Identification of ruminant mycoplasmas by dot immunobinding on membrane filtration (MF dot). , 1991, Veterinary microbiology.